__NUXT_JSONP__("/drugs/Ranibizumab", (function(a,b,c,d,e){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:b,conditionIndication:"Byooviz is indicated in adults for:The treatment of neovascular (wet) age-related macular degeneration (AMD)The treatment of visual impairment due to diabetic macular oedema (DME)The treatment of proliferative diabetic retinopathy (PDR)The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)The treatment of visual impairment due to choroidal neovascularisation (CNV)",inn:b,marketingAuthorisationDate:"2021-08-18 00:00:00",marketingAuthorisationHolder:"Samsung Bioepis NL B.V.",medicineName:"Byooviz",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fbyooviz"},{activeSubstance:b,conditionIndication:"Lucentis is indicated in adults for:The treatment of neovascular (wet) age-related macular degeneration (AMD)The treatment of visual impairment due to choroidal neovascularisation (CNV)The treatment of visual impairment due to diabetic macular oedema (DME)The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)",inn:b,marketingAuthorisationDate:"2007-01-22 01:00:00",marketingAuthorisationHolder:"Novartis Europharm Limited",medicineName:c,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Flucentis"}],fdaDrugLabel:[{brand:"LUCENTIS",indication:"1 INDICATIONS AND USAGE LUCENTIS is indicated for the treatment of patients with: LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV)",manufacturer:"Genentech, Inc.",splSetId:"de4e66cc-ca05-4dc9-8262-e00e9b41c36d"}],id:a,nciThesaurus:{casRegistry:"347396-82-1",chebiId:d,chemicalFormula:d,definition:"A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha. Ranibizumab binds to VEGF alpha and inhibits VEGF alpha binding to its receptors, VEGFR1 and VEGFR2, thereby preventing the growth and maintenance of tumor blood vessels. The molecular weight of this agent (48 kD) is much smaller than the molecular weight of bevacizumab (MW ~149 kD), allowing complete penetration of the retina and the subretinal space following intravitreal injection. In contrast to other anti-VEGF aptamers such as pegaptanib, ranibizumab has a high specificity and affinity for all soluble human isoforms of VEGF.",fdaUniiCode:"ZL1R02VT79",identifier:"C67562",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:[],synonyms:["Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor) Fab Fragment (Human-Mouse Monoclonal rhuFab V2 Gamma1 Chain), Disulfide With Human-Mouse Monoclonal rhuFab V2 Light Chain",c,"RANIBIZUMAB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FRanibizumab",extension:".json",createdAt:e,updatedAt:e}}],fetch:{},mutations:void 0}}("Ranibizumab","ranibizumab","Lucentis","","2021-10-30T13:43:14.473Z")));